Reactive and Inactive Skin Decontamination Lotion
Closed 25 days ago
This is a Sources Sought Notice only. This is not a Request for Proposal, Request for Quote, or Invitation for Bid. DLA Troop Support is seeking to identify possible sources that can manufacture the following:
Reactive Skin Decontamination Lotion (RSDL), NSN 6505-01-507-5074 and Inactive Skin Decontamination Lotion (ISDL), NSN 6910-01-507-5141. Shall be a topical lotion containing a free oxime dissolved in a maximum of polyethylene glycol monomethyl ether and water. It is intended to remove or neutralize chemical warfare (CW) agents, including many organophosphate-based pesticides and T-2 toxin from the skin. Shall be pre-impregnated in a suitable sponge applicator pad. Each applicator pad shall be individually packaged in a heat sealed polyethylene-lined aluminum foil pouch. The foil pouch shall permit easy opening of the package when wearing CW protective clothing. Shall be cleared for use by the United States (U.S.) Food and Drug Administration (FDA) for application on unbroken skin of hands, face, neck, limbs and torso.
ISDL is a training lotion that imitates the properties of the decontamination lotion in all but active decontaminating ingredients.
DLA Troop Support is in the process of developing a solicitation for the referenced item. The annual estimated required quantity is 13,249 packages (PG) Reactive Skin Decontamination Lotion (RSDL), 460 packages (PG) Inactive Skin Decontamination Lotion (ISDL). This contract contains a surge and sustainment requirement for RSDL only. The annual estimated surge and sustainment requirement is 5,504 packages per month for 6 months; total delivered amount in 6 months is 33,024 packages. Ordered quantities shall be delivered to military ordering activities or Defense Distribution Centers (DDC) located throughout the U. S. Delivery shall occur 75 days after receipt of the order.
If your firm can provide these items, please provide information with respects to the following:
Place of Manufacture
Estimated Annual Capacity
FDA registration information
Product Name and description including description of any special features
Current unit sale price
Estimated inventory level and storage requirements
Delivery days for each item
Capacity for surge and sustainment requirements
*** New Products Under Development ***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture lotions described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002.
Your Response to this RFI may be submitted electronically in pdf format and emailed to the Acquisition Specialist Rosbert.Jones@dla.mil before June 17, 2020.
This Sources Sought Notice is issued for the purpose of market research only and the Government is in no way obligated to purchase any supplies a result of this inquiry. The Government will not pay for any information submitted by respondents in response to this Sources Sought Notice.